{"hands_on_practices": [{"introduction": "Diagnosing fibromyalgia and related centralized pain syndromes has evolved from a tender point count to a more comprehensive assessment of symptom burden. The Polysymptomatic Distress (PSD) score is a crucial tool in this process, combining the extent of pain with the severity of key systemic symptoms. This practice will guide you through calculating and interpreting the PSD score, a fundamental skill for applying modern diagnostic criteria [@problem_id:4834442].", "problem": "A patient with chronic widespread pain is assessed using the American College of Rheumatology (ACR) criteria that incorporate the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS). The WPI counts the number of painful body regions among $19$ possible sites, yielding an integer score $WPI \\in [0,19]$. The SSS quantifies the severity of key symptoms (fatigue, unrefreshing sleep, cognitive symptoms) and selected somatic symptoms to yield $SSS \\in [0,12]$. The Polysymptomatic Distress (PSD) score, defined in this framework as the composite reflecting overall symptom burden in fibromyalgia and centralized pain syndromes, is given by $PSD = WPI + SSS$, and spans $[0,31]$. Given a patient with $WPI = 10$ and $SSS = 7$, compute the PSD score. Then, interpret its meaning in the clinical context of centralized pain syndromes, explicitly referencing whether the value meets the commonly used fibromyalgia classification threshold of $PSD \\geq 12$, and briefly stating the implications for centralized pain burden. Express your final numeric answer as an integer and treat the PSD as a unitless score. No rounding is required beyond reporting the exact integer value.", "solution": "The problem requires the calculation and interpretation of the Polysymptomatic Distress (PSD) score for a patient with chronic widespread pain. The problem statement is validated as scientifically grounded, well-posed, and objective, as it is based on the established American College of Rheumatology (ACR) criteria for fibromyalgia, providing all necessary definitions and data for a unique solution.\n\nThe Polysymptomatic Distress (PSD) score is defined as the sum of the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS). The governing equation is:\n$$\nPSD = WPI + SSS\n$$\nThe Widespread Pain Index, $WPI$, is an integer score representing the number of painful body regions, with a range of $WPI \\in [0, 19]$. The Symptom Severity Scale, $SSS$, is an integer score quantifying symptom severity, with a range of $SSS \\in [0, 12]$. Consequently, the $PSD$ score is an integer within the range $[0, 31]$.\n\nThe problem provides the following specific values for the patient in question:\n-   $WPI = 10$\n-   $SSS = 7$\n\nSubstituting these values into the defining equation for the $PSD$ score, we obtain:\n$$\nPSD = 10 + 7 = 17\n$$\nThe calculated $PSD$ score for this patient is $17$.\n\nThe second part of the task is to interpret this score in the clinical context of centralized pain syndromes, specifically in relation to the fibromyalgia classification threshold. The problem states that the commonly used threshold for fibromyalgia classification is $PSD \\geq 12$.\n\nWe must compare the patient's calculated score to this threshold:\n$$\n17 \\geq 12\n$$\nThis inequality is true. Therefore, the patient's score of $17$ meets the specified threshold for a fibromyalgia classification.\n\nThe implications for the patient's centralized pain burden are as follows. A $PSD$ score of $17$ on a scale that ranges from $0$ to $31$ indicates a significant level of polysymptomatic distress. This score reflects a combination of both widespread pain (an intermediate $WPI$ of $10$ out of a possible $19$) and a substantial burden of systemic symptoms such as fatigue, cognitive difficulties, and unrefreshing sleep (an intermediate-to-high $SSS$ of $7$ out of a possible $12$). In the context of centralized pain syndromes, this score confirms that the patient's clinical presentation is consistent with a diagnosis of fibromyalgia, which is considered a prototypical centralized pain syndrome. The magnitude of the score suggests a moderate-to-severe overall symptom burden that likely has a considerable negative impact on the patient's function and quality of life.", "answer": "$$\\boxed{17}$$", "id": "4834442"}, {"introduction": "Beyond symptom scoring, understanding the neurophysiological basis of fibromyalgia is key to appreciating it as a true biological disorder. Quantitative Sensory Testing (QST) offers objective measures that can reveal the hallmark features of central sensitization. This exercise challenges you to interpret a set of QST findings, including pressure pain thresholds and conditioned pain modulation, to distinguish central sensitization from localized peripheral issues [@problem_id:4834434].", "problem": "A clinician performs standardized pressure algometry in a patient with chronic widespread musculoskeletal pain. Pressure pain thresholds are measured at $10$ non-contiguous, standardized sites (bilateral trapezius, lateral epicondyle, greater trochanter, knees, and second rib). Relative to age- and sex-adjusted normative values for each site, the patient’s thresholds are uniformly $30\\%$ lower, with a site-to-site coefficient of variation of $8\\%$. There is no focal structural abnormality on imaging and no focal neurologic deficit. The patient also undergoes a Conditioned Pain Modulation (CPM) test, in which an independent conditioning stimulus produces only a $2\\%$ reduction in pain ratings compared with the expected $20\\%$ reduction observed in healthy controls. Using foundational principles about nociceptive transduction, spinal processing, and supraspinal modulation, select the single statement that best interprets whether this pattern supports central sensitization over localized peripheral pathology.\n\nA. The pattern is most consistent with central sensitization, reflecting increased central gain and impaired descending inhibition; localized peripheral pathology would not explain uniform multi-regional threshold depression.\n\nB. The pattern is most consistent with localized peripheral pathology; a single peripheral nociceptive focus routinely produces uniform multi-regional threshold reductions through segmental facilitation.\n\nC. The pattern is mechanistically nonspecific; only psychometric indices (for example, pain catastrophizing scales) can distinguish central from peripheral drivers, so the thresholds provide no inference.\n\nD. The pattern is best explained by algometer calibration error; a uniform $30\\%$ reduction across all sites implies instrument bias, making physiologic interpretation invalid.\n\nE. The pattern suggests small fiber neuropathy, which typically reduces deep pressure pain thresholds diffusely, and is thus a more plausible cause than central sensitization.", "solution": "The validity of the problem statement must be assessed prior to deriving a solution.\n\n### Step 1: Extract Givens\n-   **Patient Profile**: A patient with chronic widespread musculoskeletal pain.\n-   **Test 1**: Standardized pressure algometry.\n-   **Measurement Sites**: $10$ non-contiguous, standardized sites (bilateral trapezius, lateral epicondyle, greater trochanter, knees, and second rib).\n-   **Test 1 Result (Magnitude)**: Pressure pain thresholds (PPTs) are uniformly $30\\%$ lower than age- and sex-adjusted normative values.\n-   **Test 1 Result (Variability)**: Site-to-site coefficient of variation is $8\\%$.\n-   **Related Clinical Findings**: No focal structural abnormality on imaging and no focal neurologic deficit.\n-   **Test 2**: Conditioned Pain Modulation (CPM) test.\n-   **Test 2 Result**: An independent conditioning stimulus produces a $2\\%$ reduction in pain ratings.\n-   **Test 2 Control Data**: Expected reduction in healthy controls is $20\\%$.\n-   **Question**: Interpret whether this pattern supports central sensitization over localized peripheral pathology, based on foundational principles of nociception.\n\n### Step 2: Validate Using Extracted Givens\n1.  **Scientifically Grounded**: The problem is firmly grounded in the science of pain medicine and neurophysiology. Pressure algometry and Conditioned Pain Modulation are standard, validated methods in quantitative sensory testing (QST). The concepts of central sensitization, descending inhibition, peripheral pathology, and widespread pain are all core tenets of the field. The presented values ($30\\%$ threshold reduction, $2\\%$ CPM effect) are realistic for a patient with a centralized pain syndrome like fibromyalgia.\n2.  **Well-Posed**: The problem is well-posed. It provides a specific, quantitative set of findings and asks for the most accurate neurophysiological interpretation from a list of options. A unique, definite answer can be derived from the provided data based on established principles.\n3.  **Objective**: The problem statement is objective, clear, and uses precise clinical and scientific terminology. It is free of ambiguity, subjectivity, or opinion.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. It is scientifically sound, well-posed, and objective. I will now proceed to the solution.\n\n### Principle-Based Derivation\n\nThe problem requires an interpretation of two key findings in a patient with chronic widespread pain:\n1.  **Widespread mechanical hyperalgesia**: Pressure pain thresholds are significantly and uniformly reduced by $30\\%$ across $10$ anatomically diverse and non-contiguous body sites. Hyperalgesia is defined as an increased pain response to a stimulus that is normally painful. A reduced pain threshold signifies that a lower intensity of stimulus is required to elicit a pain response. This finding's \"widespread\" and \"uniform\" nature (indicated by the low coefficient of variation of $8\\%$) is critical. A *localized peripheral pathology* (e.g., osteoarthritis in one knee, a pinched nerve in the neck) would cause *peripheral sensitization*, leading to localized hyperalgesia in the affected area and perhaps some referred pain or secondary hyperalgesia in adjacent segments. However, it cannot account for a global, systemic state of hypersensitivity across multiple, unrelated body quadrants (e.g., arms, legs, trunk, and neck). Such a pattern points toward a centralized, rather than a localized peripheral, mechanism. This systemic hyperexcitability of the central nervous system (CNS) is often termed \"increased central gain.\"\n\n2.  **Impaired descending pain inhibition**: The Conditioned Pain Modulation (CPM) test directly assesses the functionality of the body's endogenous pain inhibitory systems. These systems involve descending pathways from the brainstem (e.g., periaqueductal gray, rostroventral medulla) that modulate nociceptive signals at the level of the spinal cord dorsal horn. In healthy individuals, a painful conditioning stimulus activates these pathways, which then inhibit the perception of a second, concurrent test stimulus, leading to a significant reduction in its perceived pain (an effect of around $20\\%$ in this case). The patient's severely attenuated response (a mere $2\\%$ reduction) is a classic sign of deficient or dysfunctional descending inhibition.\n\n**Synthesis**: The combination of widespread hyperalgesia (increased central gain) and impaired descending inhibition is the neurophysiological hallmark of **central sensitization**. Central sensitization is a state of CNS hyperexcitability that amplifies sensory input from the periphery, maintained and exacerbated by a failure of top-down inhibitory controls. This model provides a single, parsimonious explanation for the entire clinical picture.\n\n### Option-by-Option Analysis\n\n**A. The pattern is most consistent with central sensitization, reflecting increased central gain and impaired descending inhibition; localized peripheral pathology would not explain uniform multi-regional threshold depression.**\n-   **Analysis**: This statement accurately aligns the clinical findings with their underlying mechanisms. The \"uniform multi-regional threshold depression\" is correctly identified as a manifestation of \"increased central gain.\" The deficient CPM response is correctly identified as \"impaired descending inhibition.\" The statement correctly concludes that these two combined phenomena define central sensitization and that a localized peripheral issue is an inadequate explanation for the widespread nature of the findings.\n-   **Verdict**: **Correct**.\n\n**B. The pattern is most consistent with localized peripheral pathology; a single peripheral nociceptive focus routinely produces uniform multi-regional threshold reductions through segmental facilitation.**\n-   **Analysis**: This statement is incorrect. While \"segmental facilitation\" is a real phenomenon where spinal neurons become sensitized, it is largely confined to the spinal segments innervating the site of injury and adjacent areas. It does not \"routinely\" cause a *uniform* reduction in pain thresholds across *multi-regional* sites innervated by cervical, thoracic, and lumbosacral spinal nerves, as described in the problem. The extent of hyperalgesia is far too broad to be explained by a single localized focus.\n-   **Verdict**: **Incorrect**.\n\n**C. The pattern is mechanistically nonspecific; only psychometric indices (for example, pain catastrophizing scales) can distinguish central from peripheral drivers, so the thresholds provide no inference.**\n-   **Analysis**: This statement is incorrect. It wrongly dismisses the diagnostic value of quantitative sensory testing. The combination of widespread hyperalgesia and impaired CPM is a powerful and specific physiological signature of central sensitization. While psychological factors are important and often correlated, they are not the *only* nor are they a more direct way to assess the underlying neurobiology. Asserting that these objective physiological measurements provide \"no inference\" is factually wrong.\n-   **Verdict**: **Incorrect**.\n\n**D. The pattern is best explained by algometer calibration error; a uniform $30\\%$ reduction across all sites implies instrument bias, making physiologic interpretation invalid.**\n-   **Analysis**: This is an weak explanation. First, a uniform reduction relative to population norms is precisely what is expected in a systemic condition like central sensitization. Second, and more critically, this explanation completely ignores the second, independent piece of evidence: the impaired CPM response. A calibration error in the pressure algometer cannot explain a deficient physiological response in a separate CPM test. The convergence of two independent lines of evidence pointing to the same conclusion makes a physiological explanation far more plausible than an instrument error.\n-   **Verdict**: **Incorrect**.\n\n**E. The pattern suggests small fiber neuropathy, which typically reduces deep pressure pain thresholds diffusely, and is thus a more plausible cause than central sensitization.**\n-   **Analysis**: This statement is incorrect. Small fiber neuropathy (SFN) is a peripheral nerve disorder that classically affects thermal and pinprick sensation, often in a stocking-glove distribution. While it can cause widespread pain, it does not *typically* manifest as a uniform reduction in *deep pressure* pain thresholds. Moreover, SFN is a peripheral phenomenon and does not, in itself, explain the failure of the *central* descending inhibitory pathways measured by the CPM test. Central sensitization provides a more comprehensive pathogenic model that accounts for *both* the widespread deep tissue hyperalgesia and the impaired central modulation. Therefore, it is the more plausible and direct explanation.\n-   **Verdict**: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4834434"}, {"introduction": "A firm grasp of pathophysiology is essential for making rational therapeutic choices and managing patient expectations. A common clinical challenge is the use of anti-inflammatory medications in fibromyalgia, a primarily non-inflammatory condition. This scenario-based problem requires you to apply your knowledge of central versus peripheral pain mechanisms to explain the role of NSAIDs in a patient with both fibromyalgia and a comorbid nociceptive pain source like osteoarthritis [@problem_id:4834481].", "problem": "A middle-aged patient presents with chronic, diffuse musculoskeletal pain, fatigue, nonrestorative sleep, and cognitive complaints. Physical examination reveals widespread tenderness and allodynia without synovitis or focal joint effusions. Laboratory studies, including inflammatory markers, are within normal limits. The clinician establishes a diagnosis of fibromyalgia and explains that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) provided little relief previously. The patient also reports intermittent focal knee pain attributed to radiographically confirmed osteoarthritis. Which of the following statements best explains the limited benefit of NSAIDs in fibromyalgia and accurately distinguishes their appropriate role when comorbid peripheral nociceptive generators are present?\n\nA. NSAIDs are ineffective in fibromyalgia because prostaglandins are not involved in pain processing at any level of the nervous system, so NSAIDs should be avoided even in the presence of osteoarthritis.\n\nB. NSAIDs have limited benefit in fibromyalgia because the dominant mechanism is centralized pain with augmented central nervous system processing and minimal ongoing peripheral inflammatory drive; however, when coexisting nociceptive conditions (for example, osteoarthritis or tendinopathy) are present, NSAIDs can reduce peripheral prostaglandin-mediated input and thereby modestly reduce overall pain and improve function.\n\nC. NSAIDs are first-line for fibromyalgia because they inhibit central cyclooxygenase activity in the periaqueductal gray, reversing deficits in descending inhibitory pathways that drive central sensitization.\n\nD. NSAIDs should be avoided in fibromyalgia because they predictably worsen central sensitization by increasing concentrations of substance P and glutamate in the dorsal horn of the spinal cord.", "solution": "The user wants me to act as a meticulous STEM professor and solve a problem related to the management of fibromyalgia, a topic in internal medicine.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Patient Profile:** A middle-aged patient.\n*   **Presenting Symptoms:** Chronic, diffuse musculoskeletal pain, fatigue, nonrestorative sleep, and cognitive complaints (often termed \"fibro fog\").\n*   **Physical Examination Findings:** Widespread tenderness and allodynia (pain due to a stimulus that does not normally provoke pain). Absence of synovitis or focal joint effusions.\n*   **Laboratory Findings:** Normal inflammatory markers.\n*   **Diagnosis:** Fibromyalgia.\n*   **Past Medical History/Treatment:** Previous use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) provided little relief for fibromyalgia symptoms.\n*   **Comorbidity:** Intermittent focal knee pain, attributed to radiographically confirmed osteoarthritis.\n*   **Question:** The problem asks for the statement that best explains the limited efficacy of NSAIDs in fibromyalgia while also accurately describing their appropriate role when a comorbid peripheral nociceptive condition (like osteoarthritis) is present.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem statement is evaluated against the validation criteria:\n\n*   **Scientifically Grounded:** The problem describes a classic clinical presentation of fibromyalgia. The concepts presented—centralized pain, central sensitization, lack of peripheral inflammation, normal inflammatory markers, and the distinction from peripherally-driven nociceptive pain like osteoarthritis—are all well-established principles in modern rheumatology and pain medicine. The mechanism of action of NSAIDs via prostaglandin inhibition is a fundamental concept in pharmacology. The problem is scientifically sound.\n*   **Well-Posed:** The question is clearly formulated, asking for the best explanation among a set of choices. It tests the understanding of distinct pain pathophysiologies and their pharmacological implications. A unique, best answer can be determined based on established medical science.\n*   **Objective:** The language is clinical, precise, and devoid of subjective or biased statements. The case vignette is a standard, objective representation used in medical education.\n\n**Flaw Checklist:**\n1.  **Scientific or Factual Unsoundness:** None. The premises are consistent with current medical knowledge.\n2.  **Non-Formalizable or Irrelevant:** None. The problem is directly relevant to the topic.\n3.  **Incomplete or Contradictory Setup:** None. The information is sufficient to reason through the options.\n4.  **Unrealistic or Infeasible:** None. The clinical scenario is highly realistic.\n5.  **Ill-Posed or Poorly Structured:** None. The question is clear and answerable.\n6.  **Pseudo-Profound, Trivial, or Tautological:** None. The problem addresses a nuanced and clinically important distinction in pain management.\n7.  **Outside Scientific Verifiability:** None. The underlying mechanisms are subjects of scientific investigation and are part of evidence-based medicine.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is **valid**. The solution will now be derived.\n\n### Solution Derivation\n\nThe core of this problem lies in understanding the distinct pathophysiological mechanisms of pain in fibromyalgia versus osteoarthritis and how NSAIDs interact with these mechanisms.\n\n1.  **Pathophysiology of Fibromyalgia:** Fibromyalgia is predominantly a disorder of central pain processing, often termed a \"centralized pain syndrome\" or \"central sensitization.\" The primary abnormality is not located in the peripheral tissues (muscles, joints) but within the central nervous system (CNS), i.e., the brain and spinal cord. In this state, the CNS amplifies sensory input, leading to pain from stimuli that are not normally painful (allodynia) and an exaggerated pain response to painful stimuli (hyperalgesia). This central dysfunction is characterized by:\n    *   Neurotransmitter imbalances, such as increased levels of excitatory neurotransmitters (e.g., substance P, glutamate) and decreased levels of inhibitory neurotransmitters (e.g., serotonin, norepinephrine).\n    *   Impaired function of descending pain-inhibitory pathways that normally modulate nociceptive signals arriving at the spinal cord.\n    *   Crucially, fibromyalgia is considered a non-inflammatory condition. The widespread pain is not driven by peripheral inflammation, which is why systemic inflammatory markers (e.g., C-reactive protein ($CRP$), erythrocyte sedimentation rate ($ESR$)) are characteristically normal.\n\n2.  **Mechanism of Action of NSAIDs:** NSAIDs exert their analgesic, anti-inflammatory, and antipyretic effects primarily by inhibiting cyclooxygenase ($\\text{COX}$) enzymes, specifically $\\text{COX-1}$ and $\\text{COX-2}$. These enzymes are responsible for the synthesis of prostaglandins from arachidonic acid. Prostaglandins are potent inflammatory mediators that act peripherally to sensitize nociceptors (pain-sensing nerve endings), lowering their activation threshold and contributing to pain and inflammation at a site of injury or disease.\n\n3.  **NSAIDs in Fibromyalgia:** Given that the dominant pathophysiology of fibromyalgia is central sensitization and not peripheral inflammation mediated by prostaglandins, NSAIDs are generally ineffective for treating the core symptoms of fibromyalgia. They do not target the underlying neurotransmitter imbalances or dysfunctional central pain processing. This explains the patient's reported history of little relief from NSAIDs for their chronic, diffuse pain.\n\n4.  **NSAIDs in Osteoarthritis:** Osteoarthritis ($OA$), while primarily a degenerative disease, often has a secondary inflammatory component, particularly during flares. The breakdown of cartilage and changes in the subchondral bone can trigger a local inflammatory response within the joint, leading to the production of prostaglandins and other inflammatory mediators. This prostaglandin-mediated process causes peripheral sensitization and contributes significantly to the focal pain experienced in the affected joint. By inhibiting local prostaglandin synthesis, NSAIDs can effectively reduce the pain and inflammation associated with $OA$.\n\n5.  **Synthesis:** An individual with both fibromyalgia and $OA$ has two distinct sources of pain: a centralized, non-inflammatory pain from fibromyalgia and a peripherally-driven, nociceptive pain from $OA$ that can have an inflammatory component. NSAIDs are not expected to treat the former but can be very useful for the latter. Therefore, in this patient, using an NSAID would be a targeted therapy for the knee pain from $OA$. While this would not alleviate the widespread pain, fatigue, or other core fibromyalgia symptoms, it could reduce the patient's overall pain burden by treating the comorbid peripheral pain generator.\n\n### Option-by-Option Analysis\n\n*   **A. NSAIDs are ineffective in fibromyalgia because prostaglandins are not involved in pain processing at any level of the nervous system, so NSAIDs should be avoided even in the presence of osteoarthritis.**\n    *   This statement is incorrect. The assertion that prostaglandins are \"not involved in pain processing at any level of the nervous system\" is a false absolute. Prostaglandins play a critical role in peripheral sensitization and are also involved in central processes (e.g., fever generation). Furthermore, the advice to avoid NSAIDs for osteoarthritis is contrary to standard clinical practice, as they are often effective for $OA$ pain.\n    *   **Verdict:** Incorrect.\n\n*   **B. NSAIDs have limited benefit in fibromyalgia because the dominant mechanism is centralized pain with augmented central nervous system processing and minimal ongoing peripheral inflammatory drive; however, when coexisting nociceptive conditions (for example, osteoarthritis or tendinopathy) are present, NSAIDs can reduce peripheral prostaglandin-mediated input and thereby modestly reduce overall pain and improve function.**\n    *   This statement accurately captures the core concepts. It correctly identifies fibromyalgia as a centralized pain disorder, explaining the limited efficacy of peripherally-acting NSAIDs. It then correctly states that for a comorbid condition like osteoarthritis, which involves peripheral nociception and local inflammation, NSAIDs are a rational treatment choice to target that specific source of pain. The conclusion that this can \"modestly reduce overall pain\" is a precise and appropriate description of the expected outcome.\n    *   **Verdict:** Correct.\n\n*   **C. NSAIDs are first-line for fibromyalgia because they inhibit central cyclooxygenase activity in the periaqueductal gray, reversing deficits in descending inhibitory pathways that drive central sensitization.**\n    *   This statement is incorrect for two main reasons. First, NSAIDs are not considered a first-line therapy for fibromyalgia due to their general lack of efficacy. First-line therapies focus on exercise, patient education, cognitive-behavioral therapy, and centrally-acting medications such as amitriptyline, duloxetine, or pregabalin. Second, the proposed mechanism of action—reversing deficits in descending inhibitory pathways via $\\text{COX}$ inhibition in the periaqueductal gray—is not the established reason for using NSAIDs an analgesia and is not a validated mechanism for treating fibromyalgia. Clinical evidence demonstrates they are not effective for this purpose.\n    *   **Verdict:** Incorrect.\n\n*   **D. NSAIDs should be avoided in fibromyalgia because they predictably worsen central sensitization by increasing concentrations of substance P and glutamate in the dorsal horn of the spinal cord.**\n    *   This statement is incorrect. There is no robust scientific evidence to support the claim that NSAIDs \"predictably worsen central sensitization\" by this mechanism. The primary reason for not recommending NSAIDs for fibromyalgia is their lack of efficacy, not a known and predictable adverse effect on the underlying pathophysiology. While the neurochemistry of the dorsal horn is complex, this specific claim is not an established pharmacological principle.\n    *   **Verdict:** Incorrect.", "answer": "$$\\boxed{B}$$", "id": "4834481"}]}